07:00 , Apr 9, 2009 |  BC Innovations  |  Distillery Therapeutics

This week in therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) T cell receptor (TCR) Studies in mice suggest that a recombinant TCR ligand could treat MS....
08:00 , Nov 6, 2000 |  BC Week In Review  |  Clinical News

AnergiX: Phase I/II

Final results from CRXA's 31-patient Phase I/II trial showed that AnergiX.RA was safe and well tolerated at intravenous doses ranging from 0.5-150 ug/kg when given together with methotrexate, with no general immunosuppression or immunogenicity seen...
08:00 , Nov 22, 1999 |  BC Week In Review  |  Clinical News

AnergiX: Phase I

Data from 31 patients showed that AnergiX.RA was safe and well tolerated at doses ranging from 0.5-150 ug/kg when given together with methotrexate, with no general immunosuppression or immunogenicity seen. A Paulus 20 response was...
08:00 , Oct 26, 1998 |  BC Week In Review  |  Clinical News

AnergiX AG284 myelin basic protein complexed to HLA-DR2 major histocompatibility complex molecule: Phase I

ANRG said that a placebo-controlled Phase I dose-escalation study in 33 patients showed safety and tolerability of its autoimmune treatment to suppress T cells specifically involved in the disease process. Doses tested ranged from 0.6-150...
07:00 , Oct 19, 1998 |  BC Week In Review  |  Company News

Anergen autoimmune/inflammation, metabolic news

ANRG restructured its operations to conserve cash, reducing its headcount to 15-20 from about 50, and discontinuing all discovery research. The company said it will focus on the development of its AnergiX technology for rheumatoid...
07:00 , Sep 14, 1998 |  BC Week In Review  |  Company News

Anergen, Sunol deal

The companies extended their 1997 agreement to explore uses of Sunol's recombinant expression technology to produce recombinant human major histocompatibility complex (MHC) molecules. As extended, ANRG will receive an exclusive worldwide license to Sunol's single...
07:00 , Aug 10, 1998 |  BC Week In Review  |  Clinical News

Anergen regulatory update

ANRG received U.S. Patent No. 5,763,585 covering manufacturing methods for its AnergiX compounds for autoimmune diseases. AnergiX technology combines disease-specific, auto-antigenic peptides with disease-associated major histocompatibility II (MHC-II) derived proteins in a complex to inactivate...
07:00 , Jul 27, 1998 |  BC Week In Review  |  Clinical News

Anergen regulatory update

ANRG received U.S. Patent No. 5,734,023 covering the binding of the beta-chain of the major histocompatibility complex (MHC-II) molecule with autoimmune peptides. The patent covers the company's AnergiX-based compounds. Anergen Inc. (ANRG), Redwood City, Calif....
07:00 , Jul 13, 1998 |  BC Week In Review  |  Clinical News

AnergiX: ANRG began Phase I testing

Anergen Inc. (ANRG), Redwood City, Calif.   Product: AnergiX peptide from cartilage-derived glycoprotein HCgp39   Indication: Treat rheumatoid arthritis   Status: ANRG began Phase I testing in patients with RA who are taking methotrexate to...
08:00 , Mar 23, 1998 |  BC Week In Review  |  Clinical News

AnergiX:ANRG and partner N.V. Organon filed an IND with the FDA to begin a Phase I trial of AnergiX

(ANRG receives milestone, B2) Anergen Inc. (ANRG), Redwood City, Calif.   Product: AnergiX delivery technology combined with a peptide derived from HCgp39 (human cartilage-derived glycoprotein 39)   Indication: Treat rheumatoid arthritis   Status: ANRG and...